Published in AIDS Weekly, November 6th, 2006
Such response rates have never been attained in clinical trials of HIV patients living with drug-resistant virus. Fuzeon, co-developed by Roche and Trimeris (TRMS), is the first and only fusion inhibitor available for the treatment of HIV. MK-0518 is a novel investigational integrase inhibitor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.